Generics in China
Published: August 2013 · Publisher: MarketLine
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the China generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The Chinese generics market had total revenues of $35bn in 2012, representing a compound annual growth rate (CAGR) of 20.1% between 2008 and 2012.
*Market consumption volumes declined with a compound annual rate of change (CARC) of -0.2% between 2008-2012, to reach a total of 95% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 14.1% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $67.7bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in China
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the China economy
Key Questions Answered
What was the size of the China generics market by value in 2012?
What will be the size of the China generics market in 2017?
What factors are affecting the strength of competition in the China generics market?
How has the market performed over the last five years?
What are the main segments that make up China's generics market?
Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the China generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The Chinese generics market had total revenues of $35bn in 2012, representing a compound annual growth rate (CAGR) of 20.1% between 2008 and 2012.
*Market consumption volumes declined with a compound annual rate of change (CARC) of -0.2% between 2008-2012, to reach a total of 95% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 14.1% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $67.7bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in China
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the China economy
Key Questions Answered
What was the size of the China generics market by value in 2012?
What will be the size of the China generics market in 2017?
What factors are affecting the strength of competition in the China generics market?
How has the market performed over the last five years?
What are the main segments that make up China's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Bayer AG, China Grand Pharmaceutical and Healthcare Holdings Limited, Sandoz International GmbH and Sanofi
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
China Grand Pharmaceutical and Healthcare Holdings Limited 24
Sandoz International GmbH 27
Sanofi 28
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: China generics market value: $ million, 2008–12 8
Table 2: China generics market volume: % of total pharma volume, 2008–12 9
Table 3: China generics market geography segmentation: $ million, 2012 10
Table 4: China generics market value forecast: $ million, 2012–17 11
Table 5: China generics market volume forecast: % of total pharma volume, 2012–17 12
Table 6: Bayer AG: key facts 20
Table 7: Bayer AG: key financials ($) 21
Table 8: Bayer AG: key financials (€) 21
Table 9: Bayer AG: key financial ratios 22
Table 10: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts 24
Table 11: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($) 25
Table 12: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY) 25
Table 13: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios 25
Table 14: Sandoz International GmbH: key facts 27
Table 15: Sanofi: key facts 28
Table 16: Sanofi: key financials ($) 29
Table 17: Sanofi: key financials (€) 29
Table 18: Sanofi: key financial ratios 29
Table 19: China size of population (million), 2008–12 31
Table 20: China gdp (constant 2000 prices, $ billion), 2008–12 31
Table 21: China gdp (current prices, $ billion), 2008–12 31
Table 22: China inflation, 2008–12 32
Table 23: China consumer price index (absolute), 2008–12 32
Table 24: China exchange rate, 2008–12 32
LIST OF FIGURES
Figure 1: China generics market value: $ million, 2008–12 8
Figure 2: China generics market volume: % of total pharma volume, 2008–12 9
Figure 3: China generics market geography segmentation: % share, by value, 2012 10
Figure 4: China generics market value forecast: $ million, 2012–17 11
Figure 5: China generics market volume forecast: % of total pharma volume, 2012–17 12
Figure 6: Forces driving competition in the generics market in China, 2012 13
Figure 7: Drivers of buyer power in the generics market in China, 2012 15
Figure 8: Drivers of supplier power in the generics market in China, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in China, 2012 19
Figure 12: Bayer AG: revenues & profitability 22
Figure 13: Bayer AG: assets & liabilities 23
Figure 14: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability 26
Figure 15: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities 26
Figure 16: Sanofi: revenues & profitability 30
Figure 17: Sanofi: assets & liabilities 30
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Bayer AG 20
China Grand Pharmaceutical and Healthcare Holdings Limited 24
Sandoz International GmbH 27
Sanofi 28
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: China generics market value: $ million, 2008–12 8
Table 2: China generics market volume: % of total pharma volume, 2008–12 9
Table 3: China generics market geography segmentation: $ million, 2012 10
Table 4: China generics market value forecast: $ million, 2012–17 11
Table 5: China generics market volume forecast: % of total pharma volume, 2012–17 12
Table 6: Bayer AG: key facts 20
Table 7: Bayer AG: key financials ($) 21
Table 8: Bayer AG: key financials (€) 21
Table 9: Bayer AG: key financial ratios 22
Table 10: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts 24
Table 11: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($) 25
Table 12: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY) 25
Table 13: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios 25
Table 14: Sandoz International GmbH: key facts 27
Table 15: Sanofi: key facts 28
Table 16: Sanofi: key financials ($) 29
Table 17: Sanofi: key financials (€) 29
Table 18: Sanofi: key financial ratios 29
Table 19: China size of population (million), 2008–12 31
Table 20: China gdp (constant 2000 prices, $ billion), 2008–12 31
Table 21: China gdp (current prices, $ billion), 2008–12 31
Table 22: China inflation, 2008–12 32
Table 23: China consumer price index (absolute), 2008–12 32
Table 24: China exchange rate, 2008–12 32
LIST OF FIGURES
Figure 1: China generics market value: $ million, 2008–12 8
Figure 2: China generics market volume: % of total pharma volume, 2008–12 9
Figure 3: China generics market geography segmentation: % share, by value, 2012 10
Figure 4: China generics market value forecast: $ million, 2012–17 11
Figure 5: China generics market volume forecast: % of total pharma volume, 2012–17 12
Figure 6: Forces driving competition in the generics market in China, 2012 13
Figure 7: Drivers of buyer power in the generics market in China, 2012 15
Figure 8: Drivers of supplier power in the generics market in China, 2012 16
Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2012 17
Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2012 18
Figure 11: Drivers of degree of rivalry in the generics market in China, 2012 19
Figure 12: Bayer AG: revenues & profitability 22
Figure 13: Bayer AG: assets & liabilities 23
Figure 14: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability 26
Figure 15: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities 26
Figure 16: Sanofi: revenues & profitability 30
Figure 17: Sanofi: assets & liabilities 30
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.